Celgene's disclosures about ozanimod this week spur analysts' fears of a lengthy delay for a key drug
Researchers for Celgene $CELG turned up at the American Academy of Neurology meeting this week with some news about the multiple sclerosis drug ozanimod that quickly captured analysts’ attention.
In a presentation on ozanimod Phase III data, an investigator spotlighted an active metabolite produced by the drug, spurring an ah-ha moment for analysts who have been puzzling out why the FDA recently issued a stunning refuse-to-file notice on the drug.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
